METFORMIN HYDROCHLORIDE - Generic Drug Details

What are the generic sources for metformin hydrochloride and what is the scope of patent protection?

Metformin hydrochloride is the generic ingredient in twenty-one branded drugs marketed by Sun Pharm, Annora Pharma, Bionpharma, Saptalis Pharms, Vistapharm Llc, Ranbaxy, Andrx Labs Llc, Emd Serono Inc, Santarus Inc, Actavis Elizabeth, Actavis Labs Fl Inc, Ajanta Pharma Ltd, Alignscience Pharma, Alkem Labs Ltd, Amneal Pharms Ny, Apotex, Aurobindo Pharma, Aurobindo Pharma Ltd, Barr, Cspc Ouyi, Glenmark Pharms Ltd, Granules, Harman Finochem, Impax Labs, Inventia, Ivax Sub Teva Pharms, Laurus, Lupin, Lupin Ltd, Macleods Pharms Ltd, Marksans Pharma, Micro Labs, Mpp Pharma, Mylan Pharms Inc, Nostrum Pharms Llc, Novast Labs, Pharmobedient, Platinum, Prinston Inc, Qingdao Baheal Pharm, Ranbaxy Labs Ltd, Regcon Holdings, Sandoz, Sciegen Pharms, Senores Pharms, Sun Pharm Inds (in), Sun Pharm Industries, Teva, Torrent, Torrent Pharms Ltd, Twi Pharms, Unichem, Utopic Pharms, Watson Labs Inc, Yichang Humanwell, Zydus Lifesciences, Aarxion Anda Hlding, Alkem, Aurobindo, Chartwell, Dr Reddys Labs Inc, Epic Pharma Llc, Granules India, Heritage Pharma, Indicus Pharma, Ipca Labs Ltd, Mylan, Provident Pharm, Sun Pharm Inds Inc, Sunshine, Torrent Pharms, Watson Labs, Watson Labs Florida, Zydus Hlthcare, Zydus Pharms Usa, Takeda Pharms Usa, Chartwell Rx, Teva Pharms Usa, Novo Nordisk Inc, Sb Pharmco, Astrazeneca Ab, Dr Reddys Labs Sa, Msd Sub Merck, and Ph Health, and is included in one hundred and thirty-three NDAs. There are seven patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Metformin hydrochloride has twenty-nine patent family members in eight countries.

There are forty-three drug master file entries for metformin hydrochloride. Eighty-one suppliers are listed for this compound. There are eleven tentative approvals for this compound.

Summary for METFORMIN HYDROCHLORIDE

International Patents:	29
US Patents:	7
Tradenames:	21
Applicants:	84
NDAs:	133
Drug Master File Entries:	43
Finished Product Suppliers / Packagers:	81
Raw Ingredient (Bulk) Api Vendors:	164
Clinical Trials:	2,859
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for METFORMIN HYDROCHLORIDE
What excipients (inactive ingredients) are in METFORMIN HYDROCHLORIDE?	METFORMIN HYDROCHLORIDE excipients list
DailyMed Link:	METFORMIN HYDROCHLORIDE at DailyMed

Recent Clinical Trials for METFORMIN HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eurofarma Laboratorios S.A.	PHASE3
Sultan Qaboos University	PHASE4
Aspargo Labs, Inc	PHASE1

See all METFORMIN HYDROCHLORIDE clinical trials

Generic filers with tentative approvals for METFORMIN HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		500MG	TABLET, EXTENDED RELEASE;ORAL
		50MG/500MG;50MG/1000MG	TABLET;ORAL
		1000MG	TABLET;FILM COATED

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for METFORMIN HYDROCHLORIDE

Drug Class

Biguanide

Medical Subject Heading (MeSH) Categories for METFORMIN HYDROCHLORIDE

Hypoglycemic Agents

Anatomical Therapeutic Chemical (ATC) Classes for METFORMIN HYDROCHLORIDE

A10BA	Biguanides
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for METFORMIN HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RIOMET	Oral Solution	metformin hydrochloride	500 mg/5 mL	021591	1	2018-02-02
GLUMETZA	Extended-release Tablets	metformin hydrochloride	500 mg and 1000 mg	021748	1	2009-07-27
FORTAMET	Extended-release Tablets	metformin hydrochloride	500 mg and 1000 mg	021574	1	2008-10-14

US Patents and Regulatory Information for METFORMIN HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sciegen Pharms	METFORMIN HYDROCHLORIDE	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	214629-002	Feb 22, 2022	AB2	RX	No	No
Torrent Pharms	METFORMIN HYDROCHLORIDE	metformin hydrochloride	TABLET;ORAL	077711-002	Jan 24, 2007		DISCN	No	No
Harman Finochem	METFORMIN HYDROCHLORIDE	metformin hydrochloride	TABLET;ORAL	213320-001	Dec 3, 2021	AB	RX	No	No
Micro Labs	METFORMIN HYDROCHLORIDE	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212448-002	Jan 10, 2023	AB3	RX	No	No
Harman Finochem	METFORMIN HYDROCHLORIDE	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	218673-002	Jul 5, 2024	AB	RX	No	No
Actavis Labs Fl Inc	METFORMIN HYDROCHLORIDE	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	076172-001	Jun 16, 2004		DISCN	No	No
Nostrum Pharms Llc	METFORMIN HYDROCHLORIDE	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	076756-001	Jul 26, 2006	AB1	RX	No	No

Expired US Patents for METFORMIN HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Emd Serono Inc	GLUCOPHAGE XR	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021202-001	Oct 13, 2000
Emd Serono Inc	GLUCOPHAGE XR	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021202-001	Oct 13, 2000
Santarus Inc	GLUMETZA	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021748-001	Jun 3, 2005
Andrx Labs Llc	FORTAMET	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021574-002	Apr 27, 2004
Andrx Labs Llc	FORTAMET	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021574-001	Apr 27, 2004
Andrx Labs Llc	FORTAMET	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021574-002	Apr 27, 2004
Santarus Inc	GLUMETZA	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021748-002	Jun 3, 2005

International Patents for METFORMIN HYDROCHLORIDE

Country	Patent Number	Title	Estimated Expiration
Australia	2015254875
Australia	2015294912
Australia	2017254908
Australia	2018250470
Brazil	112017001968
Canada	2947528
Canada	2956902

Supplementary Protection Certificates for METFORMIN HYDROCHLORIDE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2498758	122020000018	Germany		PRODUCT NAME: METFORMIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; SAXAGLIPTIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; DAPAGLIFLOZIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/19/1401 20191111
1506211	CA 2014 00037	Denmark		PRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116
2498758	301040	Netherlands		PRODUCT NAME: METFORMINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; SAXAGLIPTINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/19/1401 20191113
1506211	122014000071	Germany		PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, GESCHUETZT DURCH DAS GRUNDPATENT EP 1 506 211; REGISTRATION NO/DATE: EU/1/13/900 20140116
1261586	15/2012	Austria		PRODUCT NAME: KOMBINATIONSPRODUKT VON SAXAGLIPTIN UND METFORMIN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON, BEINHALTEND DIE HYDROCHLORIDSALZE VON SAXAGLIPTIN UND METFORMIN; REGISTRATION NO/DATE: EU/1/11/731/001-EU/1/11/731/012 20111124
1506211	132014902277722	Italy		PRODUCT NAME: UNA COMBINAZIONE DI DAPAGLIFLOZIN O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE E METFORMINA O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE COME PROTETTI DAL BREVETTO DI BASE EP1506211(XIGDUO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/900, 20140116
1412357	50/2008	Austria		PRODUCT NAME: SITAGLIPTIN, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE ALS MONOPHOSPHAT, UND METFORMIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REGISTRATION: CH 58450 01-03 20080408

Market dynamics and financial trajectory for metformin hydrochloride: pricing trends, exclusivity timelines, competitive landscape, and revenue outlook

Last updated: June 24, 2026

Metformin hydrochloride is a long-established, off-patent generic with broad manufacturing capacity and minimal brand-driven pricing power. Market dynamics are dominated by (1) low-cost generic competition, (2) periodic formulary and payer-driven switching across immediate-release (IR) and extended-release (XR) formats, (3) supply continuity and quality events, and (4) utilization growth from type 2 diabetes and related cardiometabolic indications. Financial trajectory is characterized by steady volume growth with declining unit net prices, leading to revenue growth that tracks patient numbers and formulary placement more than product differentiation.

---

What are the key market dynamics driving metformin hydrochloride revenue today?

Answer: Revenue is driven primarily by patient utilization and formulary access, while net pricing is constrained by generic competition and tendering, with XR and combination products shaping share shifts.

How do generic price compression and tendering affect metformin net prices?

Metformin hydrochloride has no sustained brand premium in most markets due to widespread generic substitution. Net price levels typically move with:

• PBM preferred status and contracting cadence (quarterly/annual re-bids)
• State and federal tender procurement practices (where applicable)
• Channel mix shifts between retail and mail order
• Wholesale acquisition cost (WAC) versus net price gap driven by rebates and plan design

Practical implication: even when topline demand grows, profitability and incremental revenue are limited by ongoing price compression.

How do IR vs XR and dosing form factors shift demand?

Metformin is marketed in:

• Immediate-release tablets/capsules (IR)
• Extended-release formulations (XR) that reduce dosing frequency and can improve gastrointestinal tolerability for some patients
• Combination products (commonly with other glucose-lowering agents), which shift the market from pure ingredient competition to combination contracting

XR often holds share in formulary tiers when payers prefer once-daily regimens and when formulary policies reduce step therapy friction.

What utilization drivers matter most for metformin’s sales trajectory?

Primary drivers include:

• Increasing prevalence of type 2 diabetes and prediabetes screening
• Treatment intensification patterns (metformin remains a first-line anchor in many guidelines)
• Expanded use in high-risk cardiometabolic populations and polypharmacy settings
• Ongoing guideline endorsement that sustains first-line volume

Revenue impact is mainly a utilization effect. Unit price decline is offset to varying degrees by volume growth and mix to XR and combinations.

---

How strong is the patent estate for metformin hydrochloride, and when does exclusivity end?

Answer: Metformin hydrochloride is widely off-patent; exclusivity is not a typical barrier for generic entry, and competition is entrenched at the molecule level.

Why there is limited patent leverage for the active ingredient

Metformin hydrochloride itself is an old small molecule with broad generic availability. Competitive separation generally occurs at:

• Specific formulations (e.g., XR matrices)
• Specific dosing regimens and fixed-dose combinations
• Manufacturing controls and polymorph/process parameters (where patents exist at the product level)

Do formulation patents still matter for competition?

Yes, but they are narrower than molecule-level patents. Product-level patents can affect:

• Certain release profiles and excipient systems
• Bioequivalence risk management for generics attempting to launch a comparable XR product
• Later-dated changes in manufacturing or scale-up

Market implication: legal and regulatory friction is most often concentrated around particular product ANDAs and formulations, not metformin as an active ingredient.

---

What is the Orange Book status of metformin hydrochloride products?

Answer: Orange Book listings exist for multiple approved metformin and metformin XR products, but the population is dominated by generics with expiries long past for core molecule coverage.

How to interpret Orange Book coverage in an off-patent molecule

For investors and litigators, the practical reading is:

• Check each listed metformin NDA/ANDA product for “drug substance,” “drug product,” and “method of use” patents.
• For most launches, generic entry typically does not hinge on a molecule patent but on whether specific product patents are still listed and enforceable.

---

Which companies dominate metformin hydrochloride manufacturing and retail penetration?

Answer: The market is served by a wide generic manufacturer base; leadership is typically shaped by contracting power, scale production, and XR and combination breadth rather than brand-like differentiation.

What types of companies win share in metformin?

Common winners include:

• Large generic pharmaceutical manufacturers with scale and low-cost manufacturing
• Broad portfolios covering IR, XR, and combinations, enabling payer contracting across tiers
• Firms with high reliability in supply continuity and quality systems

Market implication: even if multiple manufacturers can supply, the “survivor” set is often determined by contracting and supply reliability.

---

How many Paragraph IV challenges exist for metformin hydrochloride, and what does that imply?

Answer: Paragraph IV activity is not a dominant theme for metformin at the molecule level; when it occurs, it is usually targeted to specific listed product/formulation patents for particular ANDA products.

What does the limited need for Paragraph IV suggest commercially?

• Low patent barriers lower the value of litigation-driven entry strategies.
• Generic entry tends to be “market execution” rather than “IP fight.”

---

How does metformin compare with other oral diabetes drugs on market risk and growth?

Answer: Metformin has lower competitive IP risk because it is off-patent, but it also has lower pricing upside than newer branded or specialty agents.

Competitive positioning

• Versus SGLT2 inhibitors and GLP-1 receptor agonists: metformin is cheaper, used earlier, and more broadly scalable, but has limited ability to command incremental premium.
• Versus older sulfonylureas: metformin often has better tolerability and guideline position, which supports stable utilization.

---

What manufacturing and IP barriers can still disrupt metformin supply or pricing?

Answer: Even for off-patent molecules, supply disruption can swing pricing and availability temporarily, and formulation-level IP can delay specific XR product swaps.

Supply chain and quality risks

Metformin markets can be impacted by:

• API sourcing concentration and capacity bottlenecks
• Site-specific quality events (FDA warning letters, consent decrees, or import alerts)
• Packaging and labeling changes tied to batch controls

Regulatory compliance and bioequivalence

XR products are more sensitive to formulation differences than IR. Generics can face:

• Bioequivalence complexity
• CMC changes that trigger additional review steps

These effects typically change product availability rather than the molecule’s overall demand.

---

What are the financial trajectory benchmarks for metformin hydrochloride as a product category?

Answer: Category growth depends on utilization and formulary mix; financial trajectory is typically characterized by stable-to-growing volume with declining net realized prices.

How to model metformin category revenue

High-level drivers for a financial model:

• Patient population trend (diagnosed prevalence, adherence rates, persistence)
• Prescriber preference for XR versus IR
• Mix in combination products
• Average realized net price (ARP) trend influenced by PBM rebates, competitive bidding, and tendering

Result pattern typically seen:

• Gross revenue growth tracks utilization.
• Net revenue growth lags if price declines accelerate faster than volume increases.

---

What settlement and exclusivity outcomes matter most for metformin product launches?

Answer: Settlement-driven outcomes are usually product-specific (particular ANDA ANDA-to-ANDA disputes over formulation patents) rather than molecule-level exclusivity.

Why settlements do not typically shift long-term pricing structure

Even if one product is delayed, another generic frequently supplies the market, keeping pricing pressure persistent. The key financial impact is timing of supply availability and short-term switching costs.

---

What FDA regulatory pathways affect metformin generics, including bioequivalence and labeling?

Answer: Metformin generics generally enter through Abbreviated New Drug Applications (ANDAs) with bioequivalence to reference products; XR formulations require formulation-appropriate bridging.

Key regulatory mechanics that influence market timing

• Bioequivalence study design for IR and XR differences
• Labeling changes that influence interchangeability and formulary substitution
• CMC readiness (process validation, scale-up, stability)

Market implication: the biggest near-term regulatory bottleneck is product-specific rather than molecule-level.

---

Where are the revenue and margin opportunities within metformin: XR, combos, and regional contracting?

Answer: Margins and share tend to concentrate in products with (1) formulary-friendly dosing, (2) fewer supply disruptions, and (3) combination portfolio coverage.

XR formulations

XR can improve adherence and tolerability for some patients, which can sustain higher utilization share in payer formularies compared with IR in specific channels.

Fixed-dose combinations

Combination products can carry better payer “bundle logic,” but they still face generic competition for each component and combo formulation.

Regional payer contracting

Payers can lock in a preferred generic or a small set of suppliers through aggressive contracting. The financial winners are those that maintain:

• Supply reliability
• Competitive tender terms
• Fast response to demand shifts

---

Key Takeaways

• Metformin hydrochloride is an off-patent, highly competitive market where revenue is driven mainly by patient utilization and formulary access, not by sustained exclusivity.
• Pricing is structurally constrained by generic substitution, with unit net prices subject to ongoing compression from contracting and tendering.
• Competitive differentiation is largely product-formulation and channel execution, especially XR versus IR mix and combination portfolio coverage.
• Legal risk exists at the product/formulation level, but it is not typically the primary determinant of category-level revenue trajectory.
• Financial trajectory usually shows steady or modest growth in volume with net revenue growth capped by pricing erosion.

---

FAQs

1) Does extended-release metformin have different generic entry risk than immediate-release?
Yes. XR formulation and release mechanisms can create more bioequivalence and CMC execution complexity for ANDA applicants, affecting launch timing more than molecule-level patent risk.

2) How do PBM formulary decisions typically change metformin sales mix?
They change the share between IR and XR and among competing generic suppliers by locking preferred status, which drives switching volumes and rebate-driven net price outcomes.

3) Can metformin supply disruptions materially impact prices even with generic competition?
Yes. Temporary shortages or quality-driven pullbacks can tighten supply, leading to short-term price spikes and payer restrictions until additional suppliers ramp.

4) Are combination products with metformin more resilient than metformin alone?
They can be, due to payer bundling and step therapy patterns, but they are still exposed to rapid generic entry at the combo product level.

5) What regulatory events most often delay metformin generic launches?
Product-specific CMC and bioequivalence execution issues for XR formulations, plus labeling and manufacturing changes that require additional agency review time.

---

References (APA)

No sources were provided for Orange Book status, patent estates, or financial metrics in the prompt, so no external citations are included.